Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT00426400
Other study ID # SHEBA-05-3876-HLV-CTIL
Secondary ID
Status Recruiting
Phase Phase 4
First received October 25, 2006
Last updated January 23, 2007
Start date March 2006

Study information

Verified date January 2007
Source Sheba Medical Center
Contact Hani Levkovitch-Verbin, MD
Email Hani.Verbin@ sheba.health.gov.il
Is FDA regulated No
Health authority Israel: Israeli Health Ministry Pharmaceutical Administration
Study type Interventional

Clinical Trial Summary

Our study investigates the effect of anti-aggregative treatment on success and complications of laser iridectomy. The study includes patients scheduled for laser iridectomy due to narrow angles.Patients will undergo first laser treatment with the anti-aggregative treatment and will scheduled for next lase in the other eye after discontinuing the anti-aggregative treatment. The patients will be followed-up for 3 months.


Recruitment information / eligibility

Status Recruiting
Enrollment 0
Est. completion date
Est. primary completion date
Accepts healthy volunteers No
Gender Both
Age group 20 Years and older
Eligibility Inclusion Criteria:

- patients with narrow angle that need laser iridectomy and take anti- aggregative treatment

- over 20 years old

- patients who can stop their anti-aggregative treatment for 10 days

Exclusion Criteria:

- under coumadin treatment

- post ocular surgeries

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
The cessation of anti-aggregative treatment for 10 days


Locations

Country Name City State
Israel Goldschleger Eye Institute Tel-Hashomer

Sponsors (1)

Lead Sponsor Collaborator
Sheba Medical Center

Country where clinical trial is conducted

Israel,